Automated blood test strategy could spot hidden liver disease in routine checkups

NCT ID NCT07658755

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

LiverSeek is a study testing an automated screening program for advanced liver fibrosis in people aged 50-75 with risk factors like diabetes or obesity. When a routine blood test is done, the lab system automatically calculates a fibrosis score and, if needed, orders additional tests without the doctor having to act. The goal is to see how many high-risk patients have liver scarring and whether this approach can catch it early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
automated screening strategy using blood tests (FIB-4, ELF, MASEF) and nurse-led lifestyle intervention
What this could lead to
If successful, this could lead to a simple, automated way to catch liver fibrosis early in primary care, potentially preventing progression to severe liver disease.
What could go wrong
This is an observational screening study, not a treatment trial. It may not prove that early detection improves outcomes, and the lifestyle intervention sub-study is small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital General Universitario Gregorio Marañón

    RECRUITING

    Madrid, Madrid, 28007, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.